|
May 9, 2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 3 May 2012 up to and including 9 May 2012 the Company bought 700 own shares representing 0.00053% of the share capital of the Company, to the total value of BGN 1776.6 on the Bulgarian Stock Exchange. The average price per share was BGN 2.54. The shares have been bought on the basis of the general meeting resolution of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 3073866, representing 2.33% of the share capital of the Company. May 8, 2012 The Board of Directors of Sopharma AD (the “Company”) notifies that it took the decision to establish the "Sopharma Ukraine OOD" company with headquarters in Kiev, Ukraine and with share capital of 1,000,000 / one million / UAH. The aim of the company is to optimize the trading business in Ukraine. May 4, 2012 We would like to notify that for the month of April, 2012 Sopharma AD realized increase of sales revenues of 15% compared with the same month of the previous year, including 6% decrease of domestic sales and 23% increase of export sales. During the first four months of this year, Sopharma AD realized increase of sales revenues of 1%, including 15 % decrease of domestic sales and 8% increase of export sales compared with the same quarter of 2011. May 3, 2012 We would like to notify that on 18 May 2012 (Friday) Sopharma AD will conduct a regular Annual Meeting with Investors, which will take place in the Conference center of Sopharma Business Towers. We kindly request that all interested parties notify us not later than May 11, 2012 by e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by telephone +3592 8134 319 in order to receive their registration forms. Places is limited. April 25, 2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 19 April 2012 up to and including 24 April 2012 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, to the total value of 521 BGN on the Bulgarian Stock Exchange. The average price per share was 2.61 BGN. The shares have been bought on the basis of the general meeting resolution of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 3073166, representing 2.328% of the share capital of the Company. April 19, 2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from April 12 2012 up to and including April 18 2012 the Company bought 1000 own shares representing 0.000757% of the share capital of the Company, to the total value of BGN 2642.00 on the Bulgarian Stock Exchange. The average price per share was 2.64 BGN. The shares have been bought on the basis of the general meeting resolution of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 3072966, representing 2.328% of the share capital of the Company. April 18, 2012 The Board of Directors of Sopharma AD (the “Company”) announces that it has received notifications of disclosure of shareholdings under Art. 145 of POSA: Gramercy Select Master Fund, USA, Georgetown sold 8,587,285 shares, representing 6.51% of the capital of Sopharma, thereby closing its position in the capital of "Sopharma" AD, and Gramercy Emerging Markets Fund, USA, Georgetown sold 7,980,192 shares, representing 6.05% of the capital of Sopharma, thereby closing its position in the capital of "Sopharma" AD. The date of registration of the two transactions with the Central Depository is April 9, 2012 April 18, 2012 The Board of Directors of Sopharma AD (the “Company”) announces that it took a decision to sell 8976 ordinary registered shares with voting rights, representing 51% of the capital of ZAO "Rostbalkanpharm", city of Azov, Rostov region, Russian Federation, divided into 17,600 common shares of emission with state registration № 1-01-58454-P. April 11, 2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 5 April 2012 up to and including 11 April 2012 the Company bought 500900 own shares representing 0.379% of the share capital of the Company, to the total value of BGN 1137354 on the Bulgarian Stock Exchange. The average price per share was BGN 2.27. The shares have been bought on the basis of the general meeting resolution of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 3071966, representing 2.327% of the share capital of the Company. April 5, 2012 We would like to notify that for the month of March, 2012 Sopharma AD realized decrease of sales revenues of 14% compared with the same month of the previous year, including 10% decrease of domestic sales and 16% decrease of export sales. During the last two months we managed to compensate the decrease from January, caused by force major conditions and we finish the first quarter of 2012 with 3% decrease of sales revenues compared with the same quarter of 2011, including 18% decrease of domestic sales and 3% increase of export sales. March 7, 2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 01 March 2012 up to and including 07 March 2012 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, to the total value of 570 BGN on the Bulgarian Stock Exchange. The average price per share was 2.85 BGN. The shares have been bought on the basis of the general meeting resolution of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 2520966, representing 1.910% of the share capital of the Company. March 5, 2012 We would like to notify that for the month of February, 2012 Sopharma AD realized growth of sales revenues of 20% compared with the same month of the previous year, including 10% decrease of domestic sales 33% growth of export sales. From the beginning of this year sales revenues increased with 3%, including 23% decrease of domestic sales and 13 % growth of export sales. March 1, 2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from February 23 2012 up to and including February 29 2012 the Company bought 298 own shares representing 0.000226% of the share capital of the Company, to the total value of BGN 822.67 on the Bulgarian Stock Exchange. The average price per share was 2.76 BGN. The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
February 20, 2012
February 2, 2012 Current report No. 11 /2012
NOTIFICATION OF INSIDERS’ TRANSACTIONS The Board of Directors of SOPHARMA AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade by an investment intermediary authorized to manage Mr. Donev’s portfolio of shares in the capital of SopharmaAD. Mr. Donev decided to exit his direct position in Sopharma AD due to the increased reporting requirement in Poland and in order to avoid misinterpretation as a consequence of transactions with Sopharma AD shares. Mr. Donev remains the main shareholder in the capital of Sopharma AD through his indirect participation. Legal grounds: Art.160.4 of the Act on Trading in Financial Instruments of 29 July 2005. February 2, 1012 We would like to notify that for the month of January 2012 due to the bad weather conditions Sopharma AD realized decrease in sales revenues on annual basis of 17%, including 37% for the domestic market, 9% for the export markets. January 30, 2011 Sopharma issued its Q4 2011 Individual Financial Report. It is published in the Financial Information Section -> Reports. January 27 2012 Current report No. 8/2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 19 2012 up to and including January 25 2012 the Company bought 500 own shares representing 0.00038% of the share capital of the Company, to the total value of BGN 1450 on the Bulgarian Stock Exchange. The average price per share was 2.90 BGN. The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 2520468, representing 1.909% of the share capital of the Company.January 18, 2012 Current report No. 7/2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 12 2012 up to and including January 18 2012 the Company bought 1000 own shares representing 0.00076% of the share capital of the Company, to the total value of BGN 2938 on the Bulgarian Stock Exchange. The average price per share was 2.94 BGN. The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 2519968, representing 1.910% of the share capital of the Company.January 13, 2012 Current report No. 5/2012 Dated 13 January 2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that on January 06 2012 the Company bought 11 150 shares from the capital of the company Hydroizomat AD. With this deal Sopharma AD has increased its holdings in the capital of the above-mentioned company over 5%. Sopharma AD now holds 65 222 shares or 5.02% of the capital of Hydroizomat AD. The total capital of the company is 1 299 122 shares. The transaction was conducted on the unofficial market of the Bulgarian Stock Exchange – Sofia AD Segment B. This transaction was not carried out with the purpose of gaining control. Sopharma AD is not a member of the management board of Hydroizomat AD. January 6, 2012 ACQUISITION OF OWN SHARES Current report No. 4/2012 Dated 06 January 2012 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 03 2012 up to and including January 06 2012 the Company bought 459 own shares representing 0.00034% of the share capital of the Company, to the total value of BGN 1460 on the Bulgarian Stock Exchange. The average price per share was BGN 3.19. The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 2518509, representing 1.908% of the share capital of the Company.January 6, 2012 NOTIFICATION OF INSIDERS’ TRANSACTIONS The Board of Directors of SOPHARMA AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade. Legal grounds: Art.160.4 of the Act on Trading in Financial Instruments of 29 July 2005. January 5, 2012 For the month of December, 2011 Sopharma AD realized growth of sales revenues of 38% compared with the same month of the previous year, including 48% growth of domestic sales and 29% growth of export sales. The economic and political environment in Europe, the echo of the world crises and a number of administrative obstacles limited the growth rates during 2011. Sales revenues reached almost 210 million BGN and grew with 0.41%, including 3.32% growth of the domestic market and 0.86% decrease of exports compared with the same period of 2010. “The past year forced us to adopt a management approach of balance between innovative investments in the company’s future, strengthening our positions at the existing markets and a conservative standing towards entirely new initiatives. During the second half of 2011 we came across a number of administrative problems, which disrupted our export to Russia and other significant markets. After some of these issues were solved in December 2011 we managed to realize double digit growth for Caucuses and Middle Asia, the Balkan region, Moldova, as well as growth in the export sales for the Ukraine and the Baltic states. In the first months of 2012, having all the necessary documents and licenses we expect that sales revenues will compensate the downturn in the last months of the previous year and will give us a good start of this not less challenging year.” commented the executive director of Sopharma AD, Ognian Donev PhD. December 12, 2011 Current report No. 12/2011 Dated December 12 2011 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that on December 12 2011 the Company bought 500 own shares representing less than 0.001% of the share capital of the Company, to the total value of BGN 1505 on the Bulgarian Stock Exchange. The average price per share was BGN 3.01. The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 2518509, representing 1.908% of the share capital of the Company.Legal grounds: Art. 56.1 of the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies dated 29 July 2005. December 8, 2011 Current report No. 11/2011 Dated December 8 2011 The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from December 2 2011 up to and including December 7 2011 the Company bought 653 own shares representing 0.00049% of the share capital of the Company, to the total value of BGN 2075 on the Bulgarian Stock Exchange. The average price per share was BGN 3.18. The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 2518009, representing 1.908% of the share capital of the Company.Legal grounds: Art. 56.1 of the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies dated 29 July 2005. December 6, 2011
December 5, 2011 For the month of November 2011 „SOPHARMA” AD has decrease in revenues from sales with 23% in comparison with the same month of the previous year, including same levels of domestic sales and 29% decrese in exports. Revenues for the eleven months of this year decrease with 2%, including 1% decrease on the domestic market and 2% decrease of export sales compared to the same period of 2010. December 5, 2011
December 5, 2011
November 28, 2011
November 25, 2011 The Board of Directors of SOPHARMA AD (the “Company”) announces that in accordance with resolution No. 1432/2011, the management board of the Warsaw Stock Exchange resolved: 1) to introduce as of 28 November 2011 by way of an ordinary procedure all of the shares in the share capital of the Company, i.e. 132,000,000 ordinary bearer shares in the Company, to trading on the main market of the Warsaw Stock Exchange; 2) to list the shares of the Company in the continuous trading system under the abbreviated name “SOPHARMA” and the code “SPH”. November 24, 2011 The Board of Directors of SOPHARMA AD (the "Company") informs that on 24 November 2011 the Company obtained access to the Electronic System for Information Transmission (Elektroniczny System Przekazywania Informacji - ESPI). Starting from 24 November 2011, the Company will provide its current and periodical information through ESPI. November 24, 2011 The Board of Directors of SOPHARMA AD (the "Company") informs that on 23 November 2011, in accordance with resolution No. 1422/2011, the Management Board of the Warsaw Stock Exchange admitted all of the shares in the share capital of the Company, i.e. 132,000,000 ordinary bearer shares in the Company to trading on the main market of the Warsaw Stock Exchange. The Company's intention is that trading in its shares on the Warsaw Stock Exchange commences on 28 November 2011. The Company’s shares were registered in the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) under ISIN code BG11SOSOBT18. November 3, 2011 For the month of October 2011 "Sopharma" AD retains the revenue from sales over the same month of the previous year for the domestic market and for export. Revenues from sales for the ten months of this year increased by 1%, including 1% decline on the domestic market and a 2% increase in exports over the same period of 2010. September 3, 2011 Revenues from sales for the eight months of this year increased by 5%, including 2% decline for the domestic market and a 9% increase in exports over the same period of 2010. August 3, 2011 For the month of July 2011 "Sopharma" AD reached sales growth of 9% over the same month for the previous year, including same results of domestic sales and a 20% increase in export sales. Revenues from sales for the seven months of this year increased by 8%, including 2% decline for the domestic market and 13% increase in exports over the same period of 2010. July 18, 2011 In accordance with art. 115b, para. 2, Art. 115v, para. 1 of the Public Offering of Securities and art. 37 and 37a of Regulation № 8 of 12.11.2003 years the Central Securities Depository to us, a list with the amount of dividend payable to eligible persons under Art. 115v, para. 1 and to shareholders - non-residents to 13.07.2011. The total amount voted by the General Meeting of Shareholders for dividend distribution amounts to 11.22 million BGN or 0.085 BGN eight and a half stotinki per share. In accordance with the Rules of the "Central Depository" AD, the dividend will be paid as follows: for the shareholders having open client accounts with investment firms - by the investment firm, to shareholders without accounts at investment firms - through the branches of the "Eurobank EFG - Bulgaria "AD / Postbank / country. Payment of dividend will commence on 20.07.2011 Number of shares - 132,000,000; Face value: 1.00 BGN Gross dividend per share - 0,085 BGN ISIN code: BG11SOSOBT18 July 5, 2011 For the month of June 2011 the sales revenues of "Sopharma" AD increased by 6% compared to the same period of last year. Domestic sales are on the same levle and export increased by 9%. Revenues from sales in the first six months of this year increased by 8% over the same period of 2010, including 2% decline for the domestic market and 12% increase for exports. "The trend of dominance of the share of export sales revenues continues. Double-digit growth rates for exports are observed on our traditional markets, Russia and Ukraine, and Belarus and the Baltics, and sales for Kyrgyzstan and Uzbekistan are more than twice higher than the same period of 2010.", said Executive Director of Sopharma AD, Ognian Donev, PhD. June 3, 2011 For the month of May 2011 the sales of Sopharma decreased by 1% compared to the same month last year. Domestic sales maintain the same level and exports decrease by 2% due to a temporary delay of orders for the Russian market due to new regulatory packaging requirements. Revenues from sales for the first five months of this year increased by 11% compared to the same period of 2010. including 2% decline for the domestic market and 18% increase in exports. May 16, 2011 Sopharma is the leader in the Dnevnik "Top 100" companies for 2010. Again, the company is on the top of the most successful businesses in Bulgaria. The criteria are a number of financial indicators such as revenue, revenue growth, market capitalization, liquidity and profit margins. May 13, 2011 Last week Sopharma completed the registrations of four products: - Tribestan tablets in Turkey; - Tribestan Tribestan and Vita Plus tablets in Poland and - Ambroxol Syrup in Poland. This is a step towards achieving our goal to be a strong regional player and to ensure the sustainable development of the company on new and traditional markets. May 13, 2011 On May 12, 2011 Sopharma submitted to the FSC an Application for approval of a prospectus for public offering of securities and admission of securities to trading on an EU regulated market. May 5, 2011 For April Sopharma realized 20% growth in sales compared to the same period of the previous year. The growth of export sales reached 34%, while domestic sales recorded a decline of 5%. For the first four months of the year, sales revenue increased by 15%, including 24% increase in exports and 3% decrease on the domestic market. April 13, 2011 On April 8, 2011 in Minsk, Belarus Breeze Ltd acquired 99% of the registered capital of a Tabina, Belarus. Tabina owns 14 pharmacies, united under the brand Doctor Do. Tabina's Turnover for 2010 amounted to 3.780 million EUR and the company employs 75 workers. Given that in January 2011 the company Briz, belonging to Sopharma AD acquired Interpharm who owns 19 pharmacies ans has an annual turnover of 3.7 million euros, Briz now owns a consolidated pharmacy chain of 33 pharmacies with a total turnover of 7.5 million euros. This allows Briz to become the third largest privately owned chain of pharmacies in Belarus. Briz hopes that this transaction will contribute to building good relationships with all stakeholders in accordance with the economic, ethical and social values of the Republic of Belarus. April 5, 2011 For the month of March 2011 Sopharma achieved sales growth of 19% over the same month last year including stable domestic sales and 27% increase in export sales. Revenues from sales for the first quarter of this year rose by 13%, including 2% decline for the domestic market and 21% increase for exports. "For more than two years now Sopharma shifts the focus of its sales from domestic to foreign markets to ensure sustainable development of the company. This year the trend continues with revenue from foreign markets have a dominant share of over 70%. The first three months of this year marks a double-digit growth for export to our traditional markets Russia and Ukraine, and Moldova and the Balkan region, Belarus, Kyrgyzstan and Turkmenistan are more than twice higher than the same period in 2010.", said the executive director of Sopharma, Ognyan Donev, PhD. April 4, 2011 Sopharma crossed the limit of 5% in the capital of Maritsateks AD with the sale of 20,000 shares. At present, after the completion of the transaction Sopharma owns 11,033 shares of the company's capital. Actions continue in order to optimize the investment portfolio of the company. March 25, 2011 Sopharma crossed the limit of 10% in the capital of Maritsateks AD with the sale of 10,000 shares. At present, after the completion of the transaction Sopharma owns 41,033 shares of the company's capital. Actions were taken in relation with optimizing the investment portfolio of the company. March 5, 2011 For the month of February 2011 Sopharma achieved sales growth of 9% over the same month last year including steady revenues on the domestic market and 13% increase in export sales. Revenues from sales since the beginning of this year rose by 10%, including decrease of 3% for the domestic market and an increase of 17% for export. January 8, 2011 On January 4 this year with the purchase of 5500 from the capital of Maritsateks AD, Sopharma now owns more than 10% of the capital of the company. February 4, 2011 For the month of January 2011 Sopharma achieved sales growth of 13% compared to the same month last year including 6% decrease in domestic sales and 23% increase in export sales. "The positive sales growth in foreign markets continued during this month, the results confirmed expectations for increased orders for the Russian market. Last month, the company achieved double-digit growth in traditional markets such as Russia and Ukraine compared to January 2010. ", said Ognyan Donev, PhD, CEO of Sopharma. January 27, 2011 Sopharma's subsidiary Briz Ltd based in Latvia signed an agreement to acquire ZAO Belarus pharmacies chain Interfarm, and as at January 27, 2011 the first stage of the procedure was completed (acquisition of 44%). ZAO "Interfarm" is in eighth place in sales in the retail sector of pharmaceutical products and has 19 pharmacies on the territory of Belarus. 87 professionals work in the chain and its turnover is around 3.7 million euros for 2010. Right after Sopharma acquired over 51% of Briz Ltd., Latvia in 2009 due to the synergy between both companies the exceptional results followed. Already in the first quarter of 2010 Briz Ltd. showed a remarkable growth in sales, for the whole year 2010 reaching about 9.5 % compared to 2009. For a year collaboration Briz Ltd. made two steps forward and from number 10 among distributors in Latvia in 2009 jumped up to number eight on the list for 2010. The company has 14% market share of the total wholesale trade of medicines in Latvia. Last year Briz Ltd. received a confirmation by the EMEA for the registration in the European system of pharmacovilligence, allowing the company to sign agreements approved by the Medicines Agencies of the Baltic countries for servicing many European companies. The company began work on several projects to expand its activities, the most significant of them - enter the Nordic markets - is well advanced and results of this activity can be expected as early as during 2011. Briz Ltd. is working hard on the topic of vertical integration and participation in the retail sector and in 2010 initiated a series of negotiations for the purchase of pharmacy chains. Finalization of some of them are expected in the first half of 2011. January 5, 2011 The Anti-monopoly Commission permitted a unconditional concentration requested by Sopharma in connection with the acquisition of Unipharm AD shares through the Bulgarian Stock Exchange - Sofia AD. At the date of the last quarterly report Sopharma owns over 49% of Unipharm AD. For the first nine months of 2010 Sopharma achieved sales revenues amounting to 153,966 thousand BGN and the net profit of the company amounted to 36,030 thousand BGN. For the same period Unipharm AD realized revenue of 14,137 thousand BGN and net profit of 1,773 thousand BGN. January 5, 2011 For the month of December 2010 Sopharma realized a decrease of 4% in total sales revenue compared to the same month of 2009, including 1% decrease in export sales and 6% decrease in sales for the domestic market. For the entire 2010 sales revenue rose by 13%, including 20% growth in export sales and a 1% decrease in domestic sales compared to 2009. The Executive Director of Sopharma, Ognyan Donev, PhD comments that there is a significant increase in orders for the Russian market for the first two months of 2011. January 4, 2011 The Central Laboratory of the Factory for production of medicines of the Ukrainian company OAO Vitamini owned by Sopharma received a quality certificate. Certification ensures that the analysis of production conducted in the laboratory are an indicator of quality which is recognized by the Ukrainian authorities. This completes the first stage of the overall modernization and certification of the production facilities of OAO Vitamini. December 5, 2010 For the month of November 2010 Sopharma maintained the same level of total sales revenue compared to the same month last year and achieved 2% growth in export sales and 6% decline in sales on the domestic market. Revenues from sales for the eleven months of this year rose by 15%, including with 23% growth in export sales and a 1% decrease of domestic sales over the same period of 2009. November 5, 2010 After the general meeting of the Confederation of Employers and Industrialists in Bulgaria, which was held yesterday, the new board of the organization at its first meeting elected DSc Ognyan Donev as its Chairman for a period of two years. Vice Chairman of the Board were elected CEO of Bulbank Levon Hampartsumyan and Petko Dimitrov of PriceWaterhouseCoopers. Immediately following the meeting, DSc Ognyan Donev said "I hope in the next two years we will make sure that the voice of Bulgarian business is even stronger and more understandable." November 3, 2010 For the month of October 2010 Sopharma achieved sales growth of 1% over the same month last year including 4% growth in export sales and a 4% decline in sales for the domestic market. Revenues from sales for the ten months of this year rose by 17%, including performance for the domestic market and 26% growth in export sales over the same period of 2009. November 1, 2010 On 19.10.2010 Sopharma informed the public that after a series of deals on BSE - Sofia has gained 31.25 percent of the capital of Unipharm AD. To date Sopharma already owns over 49% of Unipharm AD. The acquisition of shares followed the decision of the GM of the company, instructing the Board to continue work on acquiring a substantial direct shareholding in Unipharm AD, by purchasing shares through the BSE - Sofia. October 7, 2010 In September this year Sopharma won two awards "Product of the Year" in the Ukraine XI annual competition "Panacea 2010". In the competition the jury decided on awards in various categories, namely: "Product of the Year", "Pharmacy of the Year, pharmacy network of the Year, Person of the Year", "Company of the Year", "social project of the year. The winner in the nomination "Product of the Year" is determined according to several indicators, such as: place of the product in its segment, dynamics of growth of volumes of realization in the pharmacy network; importance of the product in the range of pharmacies price / quality ratio; ad support the product, frequency of prescribing by doctors and recommended by pharmacists, etc. Analytical data for the competition was prepared by independent Ukrainian and international marketing companies: Company Business Credit," Comcon Pharma Ukraine "," SMD "(Support in Market Development)," MDM "(Medical Data Management) and others. Sopharma won the nomination "Product of the Year" with two of our products - cough syrup Bronholitin in category" "Medications prescribed for cough and cold, syrups" and with its phyto product Carsil in category "Medications prescribed for liver diseases and bile duct, solid forms". Both products have been leading for years in the portfolio and are well known and widely used in Ukraine and many other markets where Sopharma exports its products. The awards are further proof of the good name of the company and its stable positions in the pharmaceutical market in Ukraine. October 5, 2010 For the month of September 2010 Sopharma achieved sales growth of 34% over the same month last year including 47% growth in export sales and retention of domestic sales. Revenues from sales for the nine months of this year rose by 19%, including implementation of internal market and with 29% growth in export sales over the same period in 2009, maintaining the trend of double-digit growth for our traditional markets such as Russia, Ukraine, Central Asia and Caucasus as well as our new markets - Balkans and Turkey. September 24, 2010 Today was the start of the construction of Sopharma's solid forms plant in Serbia Today the CEO of Sopharma, DSc Ognyan Donev, together with Sopharma's Serbian partner CEO of Ivanchich and Sons, Mr. Ivanchich, in the presence of the Bulgarian ambassador in Serbia MP Mr. Dimitrovand the Bulgarian trade ambassador in Serbia, Mr. Dimitrov made the first sod of Sopharma's solid forms plant in Serbia. The plant is located near Belgrade, and is designed to fully comply with European requirements. The total area of the factory is 12 thousand sq.m., the project is to build a complete production cycle from raw materials to final product including warehouses and modern laboratory complex in accordance with the requirements of GMP. The plant will provide 110 working places. The investment is € 8,000,000. September 3, 2010 For the month of August 2010 Sopharma AD realized growth in sales of 14% over the same period for the previous year, including 20% export growth and zero growth on the domestic market.
August 11, 2010 The Board of Directors of Sopharma AD launched a first procedure for redemption of shares of Sopharma AD in accordance with the authorisation granted on the AGM of shareholders, held on 23.06.2010. Under the following parameters: - Number of shares to be purchased: Up to 3,960,000 (three million nine hundred and sixty thousand), representing 3% of total shares issued by the company; - Deadline for buying - no longer than 24 month; - Minimum price of redemption - BGN 3,50; - Maximum price of redemption - BGN 5.50; - Authorized investment firm: Sofia International Securities Plc and First Financial Brokerage House Ltd. August 4, 2010 For the month of July 2010 Sopharma AD realized a decline in sales by 23% over the same month last year, including 4% sales growth for the domestic market and 42% decline in export sales due to historical heat and heavy fire conditions in Russia and neighboring countries. At the request of our partners because of the extraordinary situation in the Russian Federation in July supplies were reduced, the quantities will be carried out immediately in the third quarter. Sales revenue for the seven months of this year rose by 17%, including steady sales on the internal market and 28 percent growth in export sales for the seven months of 2009. July 30, 2010 For the first quarter of 2010 Sopharma AD reached sales revenue of 101 692 thousand BGN (23.10% growth) and a profit of 24 573 thousand BGN (14.14% growth). EBITDA amounts to 32 687 thousand BGN (15.82% growth). July 2, 2010 For the month of June 2010 Sopharma AD realized sales growth of 42% over the same month of previous year including a 66% increase in export sales and a 2% sales growth for the domestic market. Sales revenue for the six months of this year rose 23 percent, including retention of domestic sales and 38% growth in export sales to shesmesechieto 2009. June 24, 2010 Pursuant to Art. 117, para 2 of the Public Offering of Securities and art. 27, paragraph 5 of the Ordinance № 2/17.09.2003 on prospectuses for public offering of securities and the disclosure by public companies and other issuers of securities, please be informed that the General Assembly of Shareholders of Sopharma AD, held on 23.06.2010 in Sofia, Street Road Iliensko "№ 16 decided in 2009 to distribute the profit of 33 593 679.27 leva / thirty-three million five hundred and ninety three thousand six hundred seventy-nine leva and 27 st / after allocating 10% required reserve as additional reserve of the company. Dividend to shareholders is not distributed. GM approved the report of the Board of Directors on the feasibility and conditions of the transactions falling within the scope of article 114, para 1 of POSA. The General Assembly authorized the Board of Directors to conclude the transactions from the scope of article 114, para 1 of POSA in the terms and conditions pursuant to Section I, II and III of the Motivated report prepared by the Board of Directors. General Assembly of Shareholders, under the Commerce Act chl.187b and chl.111, paragraph 5 of POSA, adopted a decision to buy back own shares of the company under the following conditions: 3% of total shares issued by the company; time of completion of the purchase - no more than two (2) years, a minimum price of redemption - 2,5 leva, maximum price of redemption - 5,5 leva, the General Assembly authorized the Board of Directors of the Company to determine all other conditions of redemption and to make the necessary factual and legal actions to implement the decision of the General Assembly. (Note by IR Director: The redemption of shares will take place if it is a necessary step in the merger of Bulgarian Rose - Sevtopolis AD into Sopharma AD.) June 3, 2010 For the month of May 2010 Sopharma AD realized growth in sales by 31% compared to the same month last year including 62% increase in export sales and a 9.2 percent decline in sales for the domestic market, due to the decline of the entire hospital market - nearly 15 percent. Revenues from sales since the beginning of this year rose by 19 percent, including 31% for exports and 0.5 percent decline in domestic market. May 25, 2010 Today Sopharma AD was declared the best company in the ranking of the Exchange's Journal Blog "100 best companies on the stock exchange in Bulgaria - 2009". May 20, 2010 Bulgarian Confederation of Public Relations Awards for Sopharma contribution to the PR profession in Bulgaria. In 2010, traditional country PR Prize contest turns 10. This year's awards were intended to distinguish those who really have contributed to the development of various fields in the PR profession in Bulgaria to serve as an example and future professionals with ethical and hard work in the field of communications. The award was presented an official ceremony of PR Prize 2010 on 19 May. "I am delighted that the work of Sopharma is recognition among PR practitioners in Bulgaria. In times of crisis tried to protect not only the position of the company, but also Bulgaria, all markets where we export our products, but they are nearly 40. Showed excellent stability and kept the pace of work which contribute to the sustainability of our performance and security of our partners. "Commented DSc Ognian Donev, CEO of Sopharma after the award presentation. May 5, 2010 Sopharma AD realized growth in sales by 5% over the same month last year including with a 1.2 percent increase in domestic sales and a 7% increase in export sales. According to executive director of the company DSc Ognyan Donev for the last month on revenues for the domestic market proved to shift pressure to the Distribution industry and financial resource constraints of its customers. However, sales revenue since the beginning of this year rose 16 percent, including 2% for the domestic market and 25% for export. April 29, 2010 Sopharma AD publishes its financial statements for the first quarter of 2010. Sales revenue increased by 20% over the same period of previous year, while profits grew 35%. April 28, 2010 Sopharma AD recorded the first original Bulgarian medicine in old Europe. Federal safety in health issues of Austria registered trademark of Sopharma AD Nivaject - known as the Bulgarian market Nivalin. Registration is for injection into ampulna form in two concentrations of 5 mg and 2.5 mg. April 23, 2010 Following its strategy of offering contemporary treatment on affordable prices Sopharma presents on the Bulgarian market a new medication for treatment of high blood pressure and other heart diseases - Nebicard. In the following months another 6 molecules will be introduced on the market in order to fill up the portfolio with the last generation cardiological medications. Approximately 1,7 million people over the age of 45 in Bulgaria suffer from high blood pressure. The market of this group of medications exceeds 60 million BGN annualy and grows with about 16%. This group of medications is also on the fifth most prescribed group of medications in the world. On the offcial presentation of the product today an address towards the guests of which more than 120 are cardion specialists will be made by Dr. Anthony Heagerty, President of the International Society of Hypertension. April 23, 2010 година Sopharma increased sales with 37% in March this year. Domestic sales increased with 2% and export increased with 83%. "The 20% growth for the first quarter of this year confirm that our efforts are in the right direction. We maintain the tendency from 2009 to grow faster on our export markets. Exports grew with 32% in the first three months of 2010 whereas domestic sales grew with 2%. Sales revenues on the new markets doubled compared to the same period of 2009 - these are the Balkans and Turkey and Ukraine, Middle Asia and the Caucas region. The confidence we have after these achievments gives us grounds to revise our projections for the whole year. We believe that we can reach 12-15% growth of revenues in 2010.", commented Mr. Ognian Donev, CEO of Sopharma. Today Sopharma published its annual individual audited report. March 22, 2010 Sopharma AD published its audited annual consolidated financial statements for 2008. Audited revenues amount to 454 941 thousand BGN and net profit is 19 213 thousand BGN. March 5, 2010 In February Sopharma's sales revenues increased with 11% compared to the same period of the previous year, incl. 1% increase in domestic sales and 14% increase in exports. Sales revenues this year increased with 10% compared with the same period of last year, incl. 2% increase of domestic sales and 13% increase in exports. February 5, 2010
On January 5th this year we provided to the public information about Sopharma's sales for 2009 compared with the 2008 results. As of today we have more detailed information by region whereas the most impressive growth of sales has been realized in the Balkan countries and Turkey - more than 2.8 times, EU countries - 35.8% and Asian countries - 36.1%. More modest growth has been realized in Russia - 11.3% and USA - 6.7%. January 5, 2010 For the month of December 2009 Sopharma AD reached a percentage increase of revenues of 29% compared to December 2008, including 22% decrease of domestic sales and 95% increase of export sales. Total revenues for 2009 grew with 12% compared to the previous year. Domestic sales grow with 4% and export sales with 16%.
December 11, 2009 As at December 11, 2009 Sopharma AD reached and exceeded 5% of the capital of Unipharm AD. As a result of a transaction that took place on 9.12.2009 Sopharma AD now owns 51 590 shares of the capital of Unipharm AD, or 5.159% of the capital of the company.Unipharm AD is an established manufacturer of high quality medicinal products, conforming to the high standards of Good Manufacturing Practice. The Company aims at meeting the requirements of the market and directs its efforts towards searching new market niches to satisfy growing customer demands. The Company invests in production and scientific implementation mainly in the field of generic products. Unipharm manufactures its own products as well as products on contract manufacture for its main partner Sopharma AD as the latter take up almost one third of the total product manufacture for the passed year under review. Two thirds of Assignor's products are realized on foreign markets as Poland, Lithuania, Latvia, Russia, Ukraine, Kazakhstan, Kyrgyzstan, etc. The subject of activity of Unipharm AD is medicinal products manufacture, research and experimental activities in the field of medicinal products manufacture, verifying the quality of manufactured medicinal products, sales/supply and trading activities in the country and abroad.
December 5, 2009 For the month of November 2009 Sopharma AD reached 25% increase in revenues from sales compared with the same month of 2008, including 5% decrease in domestic sales and 41% increase in exports. The sales for the period January-November this year have increased with 0,43% compared to the whole 2008, including 8% increase for the domestic market and 11%increase in exports. The sales revenues related to 17 countries for the period are higher than the total revenues for these markets reached for the whole of 2008. Exports to Balkan countries increased 2,38 times. Exports to EU countries increased with 21% compared to the whole of 2008.
November 5, 2009 Sopharma AD increased its revenues for November, 2009 with 18% compared to the same period of last year The company increased its sales revenues for November, 2009 with 18% compared with the same period of last year. Domestic sales increased with 5% and export sales with 25% respectively. For the past ten months of 2009 the incerase of sales revenues amounts to 8% compared with the same period of last year. Since the begining of the year domestic sales increased with 10% and export sales with 8%. Sales revenues for the ten months in Ukraine, Latvia, Turkey, Turkmenistan, Vietnam and Tunis exceed last years annual sales. March 10, 2009 Sopharma AD with an approved prospectus for public offering of shares in European Market On 06. 03.2009 the Financial Supervision Commission approved the prospectus for public offering of shares of the company of a European market, which is the second decisive step towards the already announced in 2007 plans to double listing of securities on the Warsaw Stock Exchange. September 15, 2008 Revenues from sales for the eight months of this year rose by 5.58% Sopharma AD has reached a 0.21% growth in sales during August this year for export in foreign currency terms and 2.80 percent growth in the domestic market, which achieved 1.96 percent growth in total sales over the same month of previous year. Revenues from sales for the quarter this year increased by 5.58%, including 16.12% of exports in monetary terms. The company has not yet realized growth in domestic sales for the period due to the reconstruction of ampulnoto proceedings which affect the planned sales in the first two months of the year. September 8, 2008 Began paying a dividend for 2007 From 08.09.2008 year Sopharma AD started paying a dividend for 2007 as follows: For shareholders, having open client accounts with investment firms - by the investment firm. For shareholders without accounts at investment firms - through branches of Bulgarian Post Bank AD in the country April 16, 2008 New plant for production of pharmaceutical substances of plant origin. On April 18, 2008. in Kazanlak will open a new plant for production of pharmaceutical substances of plant origin. Plant is part of the production cycle of Bulgarian rose Sevtopolis AD and is a unique module for processing of medicinal herbs to medicinal substances. Design and implementation of all works comply with the requirements of Good Manufacturing Practice for medicinal and pharmaceutical substances. New building of the plant is built up area of 1580 square meters The production will take place with interrupted three-shift operation and will provide high-quality medicinal substances, which in turn will be used in the original production of phyto Sopharma AD - Tabex, Tribestan, Carsil and Nivalin. For the realization of this innovative project "Bulgarian rose Sevtopolis AD invest five million euro. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||